What we do

The Canadian Center for Vaccinology

The Canadian Center for Vaccinology is an innovative research organization designed to develop, evaluate, and generate new vaccines and vaccine technologies. Through the work of experts in diverse fields, the Center is at the forefront of a global strategy to combat infectious diseases.

Canadian Center for Vaccinology - Dalhousie University

R&D Highlights

Researcher Project Title Funding Agency Term
Halperin, Scott A phase I, observer-blind, dose-escalation study in healthy, seronegative adults to explore the safety, tolerability, and immune response to recombinant hepatitis B virus surface antigen (HbsAg) co-administered with Dynavax ImmunoStimulatory (ISS) phosphorothioate oligonucleotide. Dynavax Technologies Corporation 2000–2003
Langley, Joanne A phase I/II, observer-blind, randomized, active-controlled, multi-center trial to evaluate the safety and immunogenicity of a two-dose series of monovalent H5N1 vaccine antigens manufactured in Quebec administered without adjuvant and with two different strengths of AS03, and a monovalent H5N1 vaccine antigen manufactured in Dresden administered with two different strengths of AS03, in adults aged between 18 and 64 years. GlaxoSmithKline Biologicals, North America 2007–2008
Halperin, Scott Phase I StreptAvax™ Group A streptococcal vaccine: Safety and immunogenicity analysis in health adult volunteers. ID Biomedical Corporation 2001–2003
Langley, Joanne A phase I/II study of the safety and immunogenicity of proteosome-trivalent influenza vaccine delivered by the intranasal route to health young adults. ID Biomedical Corporation 2001–2003
Halperin, Scott A phase I randomized, blinded, placebo-controlled study evaluating the safety and immunogenicity of two dose levels of recombinant meningococcal NSPA vaccine in health adults 18 to 40 years of age. Shire Biologics Inc. 2001–2002
Halperin, Scott Phase I study of the safety and immunogenicity of a quadrivalent meningococcal (A,C,Y and W-135) polysaccharide tetanus protein conjugate vaccine in adults, toddlers, and infants. sanofi pasteur Limited 2007–2009
Halperin, Beth Phase I Immunization of women with diphtheria and tetanus toxoids combined with acellular pertussis (Tdap) during the mid third trimester of pregnancy: An evaluation of the potential for immunological protection for the neonate. sanofi pasteur Limited 2007–2011

For a comprehensive list of CCfV projects visit: http://centerforvaccinology.dal.ca/vaccine_discovery
/vaccine_discovery.htm


Did you know?
image of influenza virus

The three influenza viruses that affect humans are Influenzavirus A (humans, other mammals & birds), Influenzavirus B (humans & seals), and Influenzavirus C (humans & pigs). Influenzavirus A is responsible for most flu pandemics. The virus can be transmitted through airborne particles – coughs or sneezes – contaminated surfaces, or in the case of avian influenza, through infected bird droppings. The influenza virus can survive in sub-zero temperatures, but is easily killed with disinfectants and detergents.

BACKGROUNDER

Immunization:
Inoculation and Vaccination

Inoculation (also known as variolation) was introduced to the west by Lady Mary Wortley Montagu (1689-1762), who witnessed inoculation being
portrait of lady
practiced by physicians in Constantinople,[12] and was greatly impressed:[13] she had lost a brother to smallpox and bore facial scars from the disease herself. In 1718 she had the embassy surgeon inoculate her son, and in 1721, after returning to England, had her daughter inoculated[14]. In 1722 the Prince of Wales' daughters received inoculations[16].

The practice of inoculation slowly spread amongst the royal families of Europe, followed by general adoption amongst the rest of the population. Given the severe consequences of smallpox in Europe in the 18th century, many parents felt that the benefits outweighed the risks and so inoculated their children.[21] [22]

... more